# Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence.

> PubMed lists PMID 40821249 in Cureus as Journal Article, Review, with publication-date metadata of 2025-07-15 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40821249-vosoritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-09-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40821249-vosoritide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-40821249-vosoritide-v1.json
- Content SHA-256: `246b04d94fcb54135f05b3922d71f21e8e0ddd68a6b86c75a6c3ceb33e5b1bb0`

## Claims and source pins

### Headline

Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence. ([`pubmed-observation-pmid-40821249-2025-09-14-4938cf1e9128`](#source-pubmed-observation-pmid-40821249-2025-09-14-4938cf1e9128))

### Summary

PubMed lists PMID 40821249 in Cureus as Journal Article, Review, with publication-date metadata of 2025-07-15 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40821249-2025-09-14-4938cf1e9128`](#source-pubmed-observation-pmid-40821249-2025-09-14-4938cf1e9128))

### Paragraph 1

PubMed lists PMID 40821249 in Cureus as Journal Article, Review, with publication-date metadata of 2025-07-15 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40821249-2025-09-14-4938cf1e9128`](#source-pubmed-observation-pmid-40821249-2025-09-14-4938cf1e9128))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40821249-2025-09-14-4938cf1e9128`](#source-pubmed-observation-pmid-40821249-2025-09-14-4938cf1e9128))

## Sources

<a id="source-pubmed-observation-pmid-40821249-2025-09-14-4938cf1e9128"></a>
- **Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence. · retained source version 1:2025-09-14:current:4938cf1e9128c471ca8d22eb6eaa0171dcec187c891f924c24a2e7274a85a8b9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40821249/) (`pubmed-observation-pmid-40821249-2025-09-14-4938cf1e9128`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-40821249-vosoritide-v1.json SHA-256: 246b04d94fcb54135f05b3922d71f21e8e0ddd68a6b86c75a6c3ceb33e5b1bb0.